Biosergen is developing BSG005, a new fungicidal drug candidate for the treatment of invasive fungal infections. These infections primarily affect patients with weakened immune systems and are associated with high mortality and a growing problem of drug resistance.

BSG005 has undergone clinical development and has demonstrated a favourable safety profile. In 2026, further development was paused in connection with the company’s financing situation. Biosergen has since been working on a new long-term financing and ownership structure to enable continued development of the programme.

In brief:

• Clinical drug candidate
• Targeted at invasive fungal infections
• New financing and ownership structure being established